Download file - Northern England Strategic Clinical Networks

Northern England Strategic Clinical Networks
Haematology NSSG
Constitution
2014
Document Information
Title:
Haematology NSSG Constitution
Author:
Dr G Jones , Haematology NSSG Vice-Chair
Circulation List:
Contact Details:
Telephone:
Version History:
Date: 09.06.14
Haematology NSSG
Mrs C McNeill, Peer Review Co-ordinator
[email protected]
01138 252976
Version:
v0.3
Review Date:
May 2015
Document Control
Version
V0.3
Date
Summary
Review Date
09.06.14
updated
May 2015
1
The Constitution has been agreed by:
Position:
Name:
Organisation:
Date Agreed:
Haematology NSSG Vice- Chair
Dr G Jones
Newcastle Hospitals NHS FT
06.06.14
Position:
Name:
Organisation:
Date Agreed:
Medical Director
Dr M Prentice
Cumbria, Northumberland, Tyne and Wear Area Team
18.06.14
NSSG members agreed the Constitution on:
Date Agreed:
circulated to the group 18.6.2014 for endorsement 03.07.14
Review Date:
May 2015
2
CONTENTS
PAGE
INTRODUCTION ................................................................................................................. 4
STRUCTURE AND FUNCTION ........................................................................................... 4
13-1C-101h .......................................................................................................................... 4
Network Configuration ......................................................................................................... 4
13-1C-102h .......................................................................................................................... 4
Network Site Specific Group Membership ........................................................................... 4
13-1C-103h .......................................................................................................................... 5
Network Site Specific Group Meetings ................................................................................ 5
13-1C-104h .......................................................................................................................... 5
Work Programme and Annual Report .................................................................................. 5
CO-ORDINATION OF CARE/PATIENT PATHWAYS .......................................................... 5
13-1C-105h .......................................................................................................................... 5
Investigational Guidelines Applicable to an NSSG hosting a SIHMDS ................................ 5
13-1C-106h .......................................................................................................................... 6
Investigational Guidelines Applicable to a NSSG referring cases to a SIHMDS in another
area...................................................................................................................................... 6
13-1C-107h/ ......................................................................................................................... 6
13-1C-108h .......................................................................................................................... 6
Clinical Guidelines and Chemotherapy Treatment Algorithms ............................................. 6
13-1C-109h .......................................................................................................................... 7
Clinical Diagnostic Pathways ............................................................................................... 7
13-1C-110h .......................................................................................................................... 8
Patient Pathways ................................................................................................................. 8
PATIENT EXPERIENCE...................................................................................................... 9
13-1C-111h .......................................................................................................................... 9
Patient Experience ............................................................................................................... 9
CLINICAL OUTCOMES INDICATORS ................................................................................ 9
13-1C-112h .......................................................................................................................... 9
Clinical Outcomes Indicators and Audits.............................................................................. 9
13-1C-113h .......................................................................................................................... 9
Discussion of Clinical Trials ................................................................................................. 9
Appendix 1 – Local Referral Pathways and Levels of Care ............................................... 10
Local Referral Pathways and Levels of Care ....................... Error! Bookmark not defined.
Appendix 2 – Terms of Reference ..................................................................................... 12
Appendix 3 – NSSG Membership ...................................................................................... 17
3
INTRODUCTION
The Haematology NSSG is a multi-professional group made of health professionals from
organisations across the North of England Cancer Network covering a population of 3.06
million. This document outlines the Haematology Constitution and Terms of Reference
and will be reviewed on an annual basis.
STRUCTURE AND FUNCTION
13-1C-101h Network Configuration
Cross Reference
Named haemato-oncology MDTs with their host hospitals
and trusts, including:
 the disease type or types they cover, out of the
following: i) acute leukaemias and other myeloid
disorders, (ii) lymphoid and plasma cell malignancies
 the named commissioners or named individual
practices whose catchment populations they serve.
This is summarised in Appendix, Local Referral Pathways
and Levels of Care.
13-1C-102h
Network Site Specific Group Membership
Lead for each hospital in the network:
1. Victoria Hervey (Sunderland/South Tyneside and Chair
of NSSG)
2. Gail Jones (Newcastle and Vice Chair of NSSG)
3. Anne Lennard (Newcastle and trials)
4. Scott Marshall (Gateshead/Sunderland)
5. Fiona Keenan (Durham)
6. Ian Neilly (North Tyneside and Wansbeck)
7. Roderick Oakes (Cumbria)
8. Phil Mounter (N Tees)
9. Ray Dang (S Tees)
 The clinical oncologist is John Frew
 The pathologist is Katrina Wood
 The Radiologist is Colin Ripley
 General practice representatives are Pam Coipel and
Debbie Ashcroft
 The nurse core member is Fiona Strong
 The service improvement representative is the NSSG
chair: Victoria Hervey
 NSSG Chair: Victoria Hervey
 Representatives for teenage and young adults are Anne
Lennard and Scott Marshall
 User representative is Margaret Rowe
 The NHS member nominated with specific responsibility
for user issues and patients and carers is Fiona Strong
4


Members responsible for ensuring recruitment into
clinical trials are Anne Lennard and Bridget Workman
Secretarial and administrative support is provided by
Claire McNeill, Network Peer Review Co-ordinator or
member of the Network administration team.
Cross Reference
Annual Report
In instances when user representation is non-compliant,
the NHS member nominated with specific responsibility
for users’ issues and information for patients and carers
will liaise directly with the Network representative.
Please see Appendix 2 for NSSG Terms of Reference
Please see Appendix 3 for Membership.
13-1C-103h
Network Site Specific Group Meetings
The NSSG for Haematology will meet three times annually Annual Report
as a minimum. The group will agree and operate under the
Terms of Reference (Appendix 2). All members will be
informed of meeting dates and be included in distribution of
the Agenda and Minutes. Records of attendance will be
maintained and shared with the Cancer Unit Managers in
order to inform them of their trust representation at network
level. The group met 4 times in 2013.
Date
01.02.13
25.04.13
04.07.13
07.11.13
13-1C-104h
Time
3.00pm
3.00pm
12.00pm
10.00am
Location
Evolve Business Centre
Evolve Business Centre
Evolve Business Centre
Evolve Business Centre
Work Programme and Annual Report
The NSSG will produce an annual work programme in Annual Report/
discussion with the strategic clinical network (SCN) and Work
agree with the medical director of the relevant NHS Programme
England area team.
CO-ORDINATION OF CARE/PATIENT PATHWAYS
13-1C-105h Investigational Guidelines Applicable to an NSSG
hosting a SIHMDS
These are in production. They will include:
 investigational algorithms
 protocols for prognostication
 protocols for minimal disease monitoring
 time limits for the production of reports
 methods of sample handling and transport when
sending samples outside the SIHMDS
5
13-1C-106h
Investigational Guidelines Applicable to a NSSG
referring cases to a SIHMDS in another area
Cross Reference
The NSSG will agree the following protocols of the Guidelines
SIHMDS to which their network refers cases:
 the laboratory investigational algorithms
 protocols for prognostication and minimal disease
monitoring
 time limits for the production of the reports
 methods of sample handling and transport when
sending samples into the SIHMDS.
13-1C-107h/
13-1C-108h
Clinical Guidelines and Chemotherapy Treatment
Algorithms
In consultation with all the relevant groups clinical Guidelines
guidelines have be agreed. These cover both the
investigation and management of all malignant
haematological conditions. The chemotherapy treatment
algorithms are incorporated in the haematology guidelines.
The guidelines have been reviewed and accepted by the
chemotherapy cross cutting group. The chemotherapy
algorithms will be reviewed every 6 months (every July and
January) by the chair of the NSSG and the representative
from the chemotherapy group (Calum Polwart) and any
changes will be notified to both groups. The complete
guidelines document will be reviewed and updated every 2
years and also agreed by both groups.
6
13-1C-109h
Clinical Diagnostic Pathways
Cross Reference
These are in production. Currently all bone marrow
biopsies are reported by the haematologist of the particular
patient. All trephines and lymph nodes needing IHC are
reported by the Network’s designated haematopathologists
– these are Dr Chris Bacon, Dr Katrina Wood and Dr Peter
Carey in Newcastle. In James Cook the designated
haematopathologists who report lymph nodes are Dr Alex
Svec and Dr Montserrat Giles. In James Cook the following
haematopathologists report trephines (including those that
need IHC): Dr Alex Svec, Dr Ray Dang, Dr Jamie Maddox,
Dr Dianne Plews and Dr John Chandler.
In order to comply with peer review, it is planned for the
whole region to start reporting marrows and lymph nodes
using Haemosys. All bone marrow biopsies performed on
patients with suspected haematological malignancies in the
north of the region, outside of Newcastle, will have samples
sent to Newcastle histopathology as well. The initial report
will be done by the local haematopathologist and the
Newcastle
haematopathologists
will
review
the
slides/tissue and add to the report on haemosys. All lymph
nodes suspicious of a haematological malignancy in the
north of the region are already centrally reported in
Newcastle.
In Teesside, flow cytometry will be centrally reported in
Newcastle from Spring 2014, once staffing has been
increased to allow reporting 6 days a week. Molecular and
cytogenetic samples are already centrally reported in
Newcastle. Bone marrow biopsies (including those that
need IHC) will continue to be reported locally as the service
works well, but weekly consensus meetings between the
Newcastle and Teesside haematopathologists is planned.
There is also a plan to proceed with weekly consensus
meetings for reporting of lymph nodes with a
haematological malignancy. The NSSG and the NECN
appreciate that these are significant changes for all
haematopathologists in the region, and whilst not
completely compliant with the peer review measures, these
changes wholeheartedly support the spirit of the measures.
These pathways will be under constant review with an aim
to finding the best solution for our large geographical area
and the peer review measures.
7
13-1C-110h
Patient Pathways
Cross Reference
See Appendix 1 for local referral pathways and levels of
care.
Regarding teenage and young adults, Newcastle is the
Network’s primary treatment centre. The following are
agreed designated hospitals to treat teenage and young
adults with haematological malignancies: Sunderland,
Cumbria, North Tees and James Cook. Any new diagnosis
of cancer in a patient <25 years old is reviewed at the
T&YP specific MDT, as well as the local disease-specific
MDT.
All trusts in the region offer psychological and social
support as well as rehabilitation.
All cancers of unknown primary are referred on the CUP
MDT at each local trust.
The pathways include the following:
Guidelines
The TYACN Pathway for Initial Management
The NSSG, with the chair of the relevant TYACNCG, have
agreed the TYACN patient pathway for initial management,
including any features specific to the NSSG’s cancer site
and their host adult cancer network and incorporating their
relevant MDT contact numbers. This pathway has been
distributed to the MDT lead clinicians.
The TYA Pathway for Follow Up on Completion of First
Line Treatment
Network groups have been advised to continue to follow up
patients as per adult clinical protocols and in the meantime
if necessary to seek advice by contacting their respective
TYA Lead Clinician.
It has been acknowledged that the development of these
pathways will need specialist input from adult and
paediatric oncologists to ensure that they are robust and
clinically accurate. It has been agreed to develop a TYA
working group to address these pathways along with other
TYA service issues from across NECN.
8
PATIENT EXPERIENCE
13-1C-111h
Patient Experience
Cross Reference
The NSSG plans to review each MDT’s patient feedback Annual Report/
and actions implemented annually (every July).An Work
improvement programme can then be agreed with each Programme
MDT.
CLINICAL OUTCOMES INDICATORS
13-1C-112h
Clinical Outcomes Indicators and Audits
Cross Reference
In the course of regular meetings, the NSSG will annually Annual Report/
review the progress (or discuss the completed results, as Work
relevant), of their associated MDTs' outcome indicators and Programme
audits, which should have been carried out, or the data
examined across all its associated MDTs:
Please see the MDS policy and Information Sharing
Protocol on NECN website at:
http://www.necn.nhs.uk/information-and-audit/
The haematology NSSG aims to perform one network audit
each year. The results of this are presented at the NSSG
and are also emailed to the group. Audit is a standing
agenda on the NSSG meetings.
13-1C-113h
Discussion of Clinical Trials
Trial recruitment and portfolio is discussed at every NSSG Annual Report/
meeting. Trial performance is presented by the lead for Work
clinical trials. There is a list of trials and studies agreed by Programme
the chair of the NSSG and the networks NCRN lead
clinician.
Each MDT produces and annual report for the NSSG
(every July), together with their improvement programme.
9
Appendix 1 – Local Referral Pathways and Levels of Care
CCG Referral
Pathways
Trust
Redcar and
Cleveland and
Middlesbrough
South Tees
Hospitals
NHS FT
North Yorkshire &
York PCT
(Hambleton and
Richmond area)
Stockton on Tees
and Hartlepool
Gateshead
North Tees &
Hartlepool
NHS FT
Gateshead
Health NHS
FT
Hospital Sites
JCUH
Designated
Regional
MDT and
MDT lead
Teesside
PCO
Population
(2010 data)
696,665
Friarage
University Hospital of
Hartlepool
University Hospital of
North Tees
Queen Elizabeth
Hospital
South Tyneside
South
Tyneside NHS
FT
South Tyneside
District Hospital
Sunderland
(inc Easington)
City Hospitals
Sunderland
NHS
Foundation
Trust
Sunderland Royal
Dr Phil
Mounter
South of
Tyne and
Wear
Dr V Hervey
628,900
Disease Types Dealt Level of Care
With
Leukaemia,
lymphoma, plasma
cell malignancies and
myeloproliferative
disorders (MPDs)
Level 3 (allografts
referred to
Newcastle)
Leukaemia,
lymphoma, plasma
cell malignancies and
MPDs
All sites undertake
level 2a work.
Level 2b and 3
work from South
Tyneside and
Gateshead is
referred to
Sunderland. All
sites refer
allografts to
Newcastle
10
CCG Referral
Pathways
Trust
Newcastle
Newcastle
Upon Tyne
Hospitals
NHS FT
Northumbria
Health Care
NHS FT
N Tyneside
Northumberland
Co Durham
(North)
Co Durham
(South) and
Darlington*
Cumbria
County
Durham and
Darlington
NHS FT
North Cumbria
University
Hospital NHS
Trust
Hospital Sites
Freeman Hospital
North Tyneside
Wansbeck and
Hexham General
Hospital
University Hospital of
North Durham
Shotley Bridge
Hospitals (out patients
only)
Darlington Memorial
Hospital Bishop
Auckland Hospital (out
patients only)
Cumberland Infirmary
Carlisle
West Cumberland
Hospital
Designated
Regional
MDT and
MDT lead
North of
Tyne and
Newcastle
Dr Gail
Jones
PCO
Population
(2010 data)
1,736,154
Disease Types Dealt Level of Care
With
Leukaemia,
lymphoma, plasma
cell malignancies and
MPDs
Newcastle
undertakes all
levels of care
including allograft
work. All other
centres are active
at level 2a and
refer level 2b and
3 work including
allografts to
Newcastle
*Darlington patients are offered the option of care at James Cook University Hospital as this may be more convenient for levels 2b
and 3
11
Appendix 2 – Terms of Reference
North of England Cancer Network
Network Site Specific Group (NSSG)/Network Cross Cutting Group (NCCG)
Terms of Reference
June 2013
3. Role and Purpose of Site Specific Group
The role of NSSG is clearly outlined in the Manual of Cancer Services Quality
Measures 2013.
The NSSG should be multi-disciplinary; with representation from professionals
across the care pathway; involve users in their planning and review; and have the
active engagement of all MDT leads from the relevant associated organisations.
The NSSG should:
• agree a set of clinical guidelines and patient pathways to support the delivery
of high quality equitable services across the network
• review the quality and completeness of data, recommending corrective action
where necessary
• produce audit data and participate in open review
• ensure services are evaluated by patients and carers
• monitor progress on meeting national cancer measures and ensure actions
following peer review are implemented
• review and discuss identified risks/untoward incidents to ensure learning is
spread
• agree a common approach to research and development, working with the
network research team, participating in nationally recognised studies
whenever possible.
Responsibilities of the MDT Lead Clinician
The MDT lead clinician should:
• ensure that designated specialists work effectively together in teams such
that decisions regarding all aspects of diagnosis, treatment and care of
individual patients and decisions regarding the team’s operational policies are
multi-disciplinary decisions
• ensure that care is given according to recognised guidelines (including
guidelines for onward referrals) with appropriate information being collected
to inform clinical decision making and to support clinical governance/audit
• ensure mechanisms are in place to support entry of eligible patients into
clinical trials, subject to patients giving fully informed consent
• overall responsibility for ensuring that the MDT meetings and team meet peer
review quality measures
• ensure attendance levels of core members are maintained, in line with quality
measures
• provide the link to the NSSG either by attendance at meetings or by
nominating another MDT member to attend
• ensure MDT’s activities are audited and results documented
12
•
ensure that the outcomes of the meeting are clearly recorded, clinically
validated and that appropriate data collection is supported.
NSSG Chair, Roles and Responsibilities
The Network Site Specific Group (NSSG) Chair has overall responsibility for the
development of co-ordinated, cohesive and integrated networked cancer services
for a specific tumour site. This will be achieved primarily by ensuring that the NSSG
operates efficiently and effectively to facilitate these developments across the
network.
Specifically, the Chair should:
• ensure the group is properly represented by all the key stakeholders
operating in the care of the specific tumour site
• work with NECN to ensure all Trusts in the network are involved and primary
care is appropriately represented
• aim to ensure groups are multi-professional in nature
• take responsibility for delivering on the terms of reference for the Group
• ensure that systems and processes are in place to:
o
o
o
o
o
o
•
•
•
•
•
•
•
review (and update) local and national standards
collect minimum cancer data sets
support accreditation/quality assurance
agree common audits and bench marking
agree R&D programme/common clinical trials
facilitate user involvement in the development of services.
ensure that any Tumour specific issues of clinical governance are supported
by adequate protocols across the network
organise NSSG meetings at least twice a year
prepare the agenda for and chair NSSG meetings ensuring that adequate
time is allowed for each item under discussion and stakeholders’ views are
sought
ensure that minutes and action notes are circulated to the wider network as
appropriate
ensure a vice chair is nominated. This would support succession planning
and help in attending various meetings
agree and publish the NSSG Annual Report and work programme
lead discussions with other NSSGs on issues of common interest.
Vice Chair
The NSSG Chair is a challenging role. Good practice would be Chair and Vice
Chair (preferably one from north and one from south) this would support succession
planning.
Nomination and Selection Process
Nominations for Chair and Vice Chair to come from the NSSG followed by a
selection process.
13
Term of Office
2 years with an option to a further 2 years (maximum 4 years Term of Office). The
Chair and the Vice Chair may agree to switch role after 1-2 years.
Support




employing Trust
the chair must secure its own Trust support to undertake the role
the role must be reflected in Job Plan as 0.5 PA per month
NECN staff/ team.
Ground Rules for Networking
Introduction
These ground rules preserve the principles underpinning clinical networking. The
principles may be summarised as follows:
• they prevent destructive competition between MDTs for their catchment
populations
• they prevent destructive competition between NSSGs for their associated MDTs
• they allow the development of consistent, intra- and inter-team patient pathways
which are clinically rational and in only the patients’ best interests instead of in the
vested interests of professional groups or of NHS statutory institutions.
Before a first peer review assessment of any services which, from the networking
point of view, come under the governance of a strategic clinical network (SCN),
there should be an agreement between the relevant SCNs which describes which
provider and commissioner networks come under the governance of each particular
SCN. The agreement should delineate the boundaries and list the constituent
services and commissioners of those networks. On principle, a single SCN should
be agreed as being responsible for the network. This specifies the governance
framework within which the networks are placed. Ideally this would apply to all
services in a geographical area. However, the arrangements in terms of the
governance and ownership of staff and facilities may not be coterminous across
different disease sites spread over a similar geographical area. The network
function will therefore be reviewed at a disease site specific level. The term
‘network’ in these measures refers to the disease site clinical network unless
otherwise specified. The geographical extent of this and the physical facilities and
hospital sites involved should be agreed between the relevant SCNs prior to review,
and a named SCN should be considered having ownership and
requiring/commissioning the review. This principle becomes especially important for
cases of clinical networks for the rarer cancers where catchment areas may overlap
those of more than one SCN.
NSSGs
• the NSSG should be the only such NSSG for the MDTs which are associated
with it
• for cancer sites where there is only one level of MDT, the NSSG should be
associated with more than one MDT
14
•
for cancer sites where there is a division into more than one level of MDT, i.e.
into local and specialist/supranetwork MDTs, the NSSG need only be
associated with one specialist/supranetwork MDT as long as it is associated
with more than one MDT for the cancer site overall.
Notes: The NSSG need only be associated with one specialist/supranetwork type
MDT but may be associated with more than one.
Cross Cutting Groups
These currently include network groups for:
• chemotherapy
• radiotherapy
• acute oncology.
These groups need to have working relationships with the hospitals/services system
and also the NSSGs /MDTs system, if they are to fulfil their role of acting as leaders
of the networking process. Because these groups are service specific, not cancer
site specific, it seems most important to lay down ground rules to ensure clarity and
co-ordination across a given cross cutting service within a network, and leave
ground rules regarding the relationship with NSSGs/MDTs, at a more informal and
flexible level. The term ‘network’ here refers to the networking arrangements and
coverage of the service in question.
These services are required to have local multi-professional management teams.
These are not equivalent to the site specific groups and are treated differently in the
measures. The ground rules for MDTs do not apply to them.
•
The network group for a given service should be the only such group for that
service for all the hospitals/services it is associated with.
• The equivalent reciprocal ground rules to this for hospitals and services
would be; any given hospital should be associated with only one network
group for any given service, and any service should be associated with only
one network service group.
Note: Hospitals and services are mentioned separately because, for the purposes of
peer review and data gathering, it has been necessary to clearly define individual
services and delineate their boundaries in terms of staff and facilities. Sometimes a
declared ‘service’ may cross more than one hospital.
MDTs
For MDTs dealing with cancer sites for which the IOG and measures recommend
only one level of MDT (i.e.no division into local and specialist or their equivalent.
E.g. Breast MDTs):
• The MDT should be the only such MDT for its cancer site, for its catchment
area.
Notes: The principle of a given primary care practice agreeing that patients will be
referred to a given MDT is not intended to restrict patient or GP choice. A rational
network of MDTs, rather than a state of destructive competition can only be
developed if i) there is an agreement on which MDT the patients will normally be
referred to and ii) the resulting referral catchment populations and /or workload are
15
counted, for planning purposes. It is accepted that individual patients will, on
occasion, be referred to different teams, depending on specific circumstances.
•
This ground rule does not apply to the carcinoma of unknown primary (CUP)
MDT or the specialist palliative care (SPC) MDT. This is because, for this
ground rule to be implementable, it is necessary to define a relevant disease
entity in terms of objective diagnostic criteria which governs referral at
primary care level. This is not possible for CUP or SPC, by the nature of
these practices.
• The MDT should be the only such MDT for its cancer site on or covering a
given hospital site.
Note: This is because for patient safety and service efficiency, there should be no
rival individuals or units working to potentially different protocols on the same site.
This does not prevent a given MDT working across more than one hospital site.
Neither does it prevent trusts which have more than one hospital site, having more
than one MDT of the same kind, in the trust. This ground rule does not apply to SPC
MDTs, since there may be more than one distinctive setting for the practice of SPC
on a single given hospital
site.
•
The MDT should be associated with a single named network site specific
group (NSSG) for the purposes of coordination of clinical guidelines and
pathways, comparative audits and coordination of clinical trials.
Note: MDTs which are IOG compliant but deal with a group of related cancer sites,
rather than a single site, may be associated with more than one NSSG, but should
have only one per cancer site. E.g. A brain and CNS tumours MDT also dealing with
one or more of the specialist sites such as skull base, spine and pituitary could be
associated with a separate NSSG for each of its specialty sites.
For cancer sites for which there is a division into local, specialist and in some cases,
supranetwork MDTs, the following apply to the specialist/supranetwork MDTs. The
above ground rules still apply to the ‘local’ type MDTs
• The
specialist/supranetwork
MDT
should
be
the
only
such
specialist/supranetwork
MDT
for
its
cancer
site,
for
its
specialist/supranetwork referral catchment area
• The
specialist/supranetwork
MDT
should
be
the
only
such
specialist/supranetwork MDT for its cancer site on or covering a given
hospital site
• The specialist MDT should act as the ‘local’ type MDT for its own secondary
catchment population. If a supranetwork MDT deals with potentially the whole
patient pathway for its cancer site, this ground rule applies to the
supranetwork MDT. If it deals with just a particular procedure or set of
procedures, not potentially the whole patient pathway, it does not apply.
Note: This is in order that the specialist/supranetwork MDT is exposed to the full
range of clinical practice for its cancer site. The specialist MDT should be
associated with a single named network site specific group (NSSG), (or possibly
one per individual cancer site, as above) for the purposes of coordination of clinical
guidelines and pathways, comparative audits and coordination of clinical trials.
Review Date: June 2015
16
Appendix 3 – NSSG Membership
HAEMATOLOGY NSSG MEMBERSHIP
ORGANISATION
NAME
DESIGNATION
CITY HOSPITALS
SUNDERLAND NHS
FOUNDATION TRUST
COUNTY DURHAM &
DARLINGTON NHS
FOUNDATION TRUST
GATESHEAD HEALTH NHS
FOUNDATION TRUST
NEWCASTLE UPON TYNE
HOSPITALS NHS
FOUNDATION TRUST
Faye Laverick
Victoria Hervey
Haematology Clinical Nurse Specialist
Consultant Haematologist
Deborah Grimes
Fiona Keenan
Shirley Tervit
Scott Marshall
Haematology Clinical Nurse Specialist
Consultant Haematologist
Haematology Clinical Nurse Specialist
Consultant Haematologist
Peter Carey
John Frew
Gail Jones
Anne Lennard
Katrina Wood
Colin Ripley
Roderick Oakes
Consultant Haematologist
Consultant Clinical Oncologist
Consultant Haematologist
Consultant Haematologist
Consultant Histopathologist
Consultant Radiologist
Consultant Haematologist
Philip Mounter
Consultant Haematologist
Ian Neilly
David Tompkins
Gill Starkey
Consultant Haematologist
Haematology Clinical Nurse Specialist
Lead Cancer Nurse
Ray Dang
Consultant Haematologist
Jan Brandon
Pam Mclinn
Victoria Hervey
MDT Co-ordinator
Clinical Trials Practitioner
Consultant Haematologist
John Pattison
Debbie Ashcroft
Pam Coipel
Debbie Ashcroft
Calum Polwart
Haematology Nurse Specialist
GP Cancer Lead
GP Cancer Lead
GP Cancer Lead
Network Pharmacist
Ann Bassom
Tony Branson
Carol Mayes
Roy McLachlan
Penny Williams
Network PA
Medical Director
Network Delivery Facilitator
Network Associate Director
Research Manager
NORTH CUMBRIA
UNIVERSITY HOSPITALS NHS
TRUST
NORTH TEES & HARTLEPOOL
NHS FOUNDATION TRUST
NORTHUMBRIA HEALTHCARE
NHS FOUNDATION TRUST
On electronic distribution list for
information
SOUTH TEES HOSPITALS NHS
FOUNDATION TRUST
On electronic distribution list for
information
SOUTH TYNESIDE NHS
FOUNDATION TRUST
NORTH OF ENGLAND
CANCER NETWORK
On electronic distribution list for
information
17

Download Report